Connecting the dots between tau dysfunction and neurodegeneration

Trends in Cell Biology

Volumn 25, Issue 1, 2015, Pages 46-53

  Frost, Bess ^a   Götz, Jürgen ^b   Feany, Mel B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Actin; Alzheimer; Cell cycle; Chromatin; Tauopathy; Therapeutics

Indexed keywords

ACTIN FILAMENT; CELL ACTIVATION; CELL CYCLE; CELL LOSS; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; ELECTRIC POWER PLANT; EPIGENETICS; HISTOPATHOLOGY; HUMAN; NERVE CELL; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; POSTMITOTIC NEURON; REVIEW; SYNAPSE; TAU NEUROTOXICITY; TAUOPATHY; ANIMAL; DISEASE MODEL; GLIA; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

TAU PROTEIN;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NERVE DEGENERATION; NEUROGLIA; NEURONS; SIGNAL TRANSDUCTION; TAU PROTEINS; TAUOPATHIES;

EID: 84918576232     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.07.005     Document Type: Review

References (90)

1. Alzheimer A., et al. An English translation of Alzheimer's 1907 paper, 'Uber eine eigenartige Erkankung der Hirnrinde'. Clin. Anat. 1995, 8:429-431.
2. Grundke-Iqbal I., et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261:6084-6089.
3. Poorkaj P., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43:815-825.
4. Hutton M., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
5. Spillantini M.G., et al. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. Am. J. Pathol. 1998, 153:1359-1363.
6. Roberson E.D., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
7. Ittner L.M., Gotz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
8. Gotz J., et al. Tau-targeted treatment strategies in Alzheimer's disease. Br. J. Pharmacol. 2012, 165:1246-1259.
9. Medina M., Avila J. New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. Biochem. Pharmacol. 2014, 88:540-547.
10. Ke Y.D., et al. Lessons from tau-deficient mice. Int. J. Alzheimers Dis. 2012, 2012:873270.
11. Mhatre S.D., et al. Invertebrate models of Alzheimer's disease. J. Alzheimers Dis. 2013, 33:3-16.
12. LaFerla F.M., Green K.N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006320.
13. Bloom G.S. Amyloid-beta and Tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014, 71:505-508.
14. Davies C.A., et al. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 1987, 78:151-164.
15. Masliah E., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001, 56:127-129.
16. Scheff S.W., et al. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:1372-1384.
17. Scheff S.W., et al. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68:1501-1508.
18. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
19. Ittner L.M., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
20. Leroy K., et al. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am. J. Pathol. 2012, 181:1928-1940.
21. Roberson E.D., et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:700-711.
22. 2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010, 30:11938-11950.
23. Boehm J. A 'danse macabre': tau and Fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity. Eur. J. Neurosci. 2013, 37:1925-1930.
24. Frandemiche M.L., et al. Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J. Neurosci. 2014, 34:6084-6097.
25. Cuchillo-Ibanez I., et al. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J. 2008, 22:3186-3195.
26. Hinrichs M.H., et al. Tau protein diffuses along the microtubule lattice. J. Biol. Chem. 2012, 287:38559-38568.
27. Aronov S., et al. Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J. Neurosci. 2001, 21:6577-6587.
28. Li X., et al. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J. 2011, 30:4825-4837.
29. Morel M., et al. Levels of kinesin light chain and dynein intermediate chain are reduced in the frontal cortex in Alzheimer's disease: implications for axoplasmic transport. Acta. Neuropathol. 2012, 123:71-84.
30. Hendricks A.G., et al. Motor coordination via a tug-of-war mechanism drives bidirectional vesicle transport. Curr. Biol. 2010, 20:697-702.
31. Xu J., et al. Interplay between velocity and travel distance of Kinesin-based transport in the presence of Tau. Biophys. J. 2013, 105:L23-L25.
32. Xu J., et al. Tuning multiple motor travel via single motor velocity. Traffic 2012, 13:1198-1205.
33. Ittner L.M., et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15997-16002.
34. Ittner L.M., et al. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 2009, 284:20909-20916.
35. Falzone T.L., et al. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum. Mol. Genet. 2010, 19:4399-4408.
36. Ke Y.D., et al. Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. PLoS ONE 2012, 7:e35678.
37. Henriquez J.P., et al. Subpopulations of tau interact with microtubules and actin filaments in various cell types. Cell Biochem. Funct. 1995, 13:239-250.
38. Galloway P.G., et al. Hirano body filaments contain actin and actin-associated proteins. J. Neuropathol. Exp. Neurol. 1987, 46:185-199.
39. Galloway P.G., et al. Hirano bodies contain tau protein. Brain Res. 1987, 403:337-340.
40. Davis R.C., et al. A cell culture model for investigation of Hirano bodies. Acta Neuropathol. 2008, 115:205-217.
41. Fulga T.A., et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat. Cell Biol. 2007, 9:139-148.
42. Moraga D.M., et al. A tau fragment containing a repetitive sequence induces bundling of actin filaments. J. Neurochem. 1993, 61:979-986.
43. He H.J., et al. The proline-rich domain of tau plays a role in interactions with actin. BMC Cell Biol. 2009, 10:81.
44. Semenova I., et al. Actin dynamics is essential for myosin-based transport of membrane organelles. Curr. Biol. 2008, 18:1581-1586.
45. Gourlay C.W., et al. A role for the actin cytoskeleton in cell death and aging in yeast. J. Cell Biol. 2004, 164:803-809.
46. Gourlay C.W., Ayscough K.R. Actin-induced hyperactivation of the Ras signaling pathway leads to apoptosis in Saccharomyces cerevisiae. Mol. Cell. Biol. 2006, 26:6487-6501.
47. DuBoff B., et al. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 2012, 75:618-632.
48. Kidd M. Alzheimer's disease - an electron microscopical study. Brain 1964, 87:307-320.
49. Baloyannis S.J. Mitochondrial alterations in Alzheimer's disease. J. Alzheimers Dis. 2006, 9:119-126.
50. Schagger H., Ohm T.G. Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur. J. Biochem. 1995, 227:916-921.
51. David D.C., et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005, 280:23802-23814.
52. Schulz K.L., et al. A new link to mitochondrial impairment in tauopathies. Mol. Neurobiol. 2012, 46:205-216.
53. Wang X., et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009, 29:9090-9103.
54. Quintanilla R.A., et al. Truncated tau and Abeta cooperatively impair mitochondria in primary neurons. Neurobiol. Aging 2012, 33:619.e25-619.e35.
55. Rhein V., et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20057-20062.
56. Schmitt K., et al. Insights into mitochondrial dysfunction: aging, amyloid-beta, and tau-A deleterious trio. Antioxid. Redox Signal. 2012, 16:1456-1466.
57. Cente M., et al. Expression of a truncated human tau protein induces aqueous-phase free radicals in a rat model of tauopathy: implications for targeted antioxidative therapy. J. Alzheimers Dis. 2009, 17:913-920.
58. Stamer K., et al. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 2002, 156:1051-1063.
59. Lu T., et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 2014, 507:448-454.
60. Hanawalt P.C., et al. Genomic heterogeneity of DNA repair. Role in aging?. Ann. N. Y. Acad. Sci. 1992, 663:17-25.
61. McKinnon P.J. Maintaining genome stability in the nervous system. Nat. Neurosci. 2013, 16:1523-1529.
62. Mullaart E., et al. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol. Aging 1990, 11:169-173.
63. Bradley-Whitman M.A., et al. Nucleic acid oxidation: an early feature of Alzheimer's disease. J. Neurochem. 2014, 128:294-304.
64. Khurana V., et al. A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell 2012, 11:360-362.
65. Katsel P., et al. Cycle checkpoint abnormalities during dementia: a plausible association with the loss of protection against oxidative stress in Alzheimer's disease. PLoS ONE 2013, 8:e68361.
66. Violet M., et al. A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front. Cell. Neurosci. 2014, 8:84.
67. Sultan A., et al. Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem. 2011, 286:4566-4575.
68. Frost B., et al. Tau promotes neurodegeneration through global chromatin relaxation. Nat. Neurosci. 2014, 17:357-366.
69. Dillon N. Heterochromatin structure and function. Biol. Cell 2004, 96:631-637.
70. Payao S.L., et al. Differential chromosome sensitivity to 5-azacytidine in Alzheimer's disease. Gerontology 1998, 44:267-271.
71. Zhang K., et al. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 2012, 12:1261-1268.
72. Mastroeni D., et al. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS ONE 2009, 4:e6617.
73. Mastroeni D., et al. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol. Aging 2010, 31:2025-2037.
74. Lu J., et al. Visualizing the microtubule-associated protein tau in the nucleus. Sci. China Life Sci. 2014, 57:422-431.
75. Luna-Munoz J., et al. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. J. Alzheimers. Dis. 2005, 8:29-41.
76. Sjoberg M.K., et al. Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. J. Cell Sci. 2006, 119:2025-2034.
77. Brennecke J., et al. Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell 2007, 128:1089-1103.
78. Aravin A., et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature 2006, 442:203-207.
79. Arendt T. Cell cycle activation and aneuploid neurons in Alzheimer's disease. Mol. Neurobiol. 2012, 46:125-135.
80. Dias-Santagata D., et al. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J. Clin. Invest. 2007, 117:236-245.
81. Khurana V., et al. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr. Biol. 2006, 16:230-241.
82. Absalon S., et al. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J. Neurosci. 2013, 33:14645-14659.
83. Huse J.T., et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009, 23:1327-1337.
84. Herrup K., Busser J.C. The induction of multiple cell cycle events precedes target-related neuronal death. Development 1995, 121:2385-2395.
85. Ballard C., et al. Alzheimer's disease. Lancet 2011, 377:1019-1031.
86. Frost B., et al. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284:12845-12852.
87. Clavaguera F., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
88. Kim W., et al. Interneuronal transfer of human tau between Lamprey central neurons in situ. J. Alzheimers Dis. 2010, 19:647-664.
89. Holmes B.B., et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E3138-E3147.
90. Walker L.C., et al. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013, 70:304-310.